1 Hematology, ASST Cremona, Cremona, Italy.
2 Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
3 Statistician - Centro Coordinamento Ricerche Cliniche, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
4 Anatomic Pathology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy..
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background and objectives: Mutations of the TP53 gene have an unfavorable prognosis in Myelodysplastic Syndromes (MDS). The product of the TP53 gene is the p53 protein. Most of the TP53
mutations entail the accumulation of the protein in the nucleus of
tumor cells. The immunohistochemical (IHC) staining for p53 can be a
surrogate suggesting a mutational status and, if overexpressed, seems
to be of prognostic value by itself. The best prognostic cut-off value
of overexpression is controversial. The aim of this pilot study is to
investigate the correct value from a homogenous group of patients with
higher IPSS-R risk MDS.
Material and Methods
|Table 1. Patients’ characteristics.|
|Table 2 . Better cut-off value analysis. It is intended as the result of comparing survivorship of the cohort above or equal to cutpoint versus that of the cohort below the cutpoint.|
|Figure 2. Overall Survival According to the p53 cutoff value.|